BIIB
Price
$132.15
Change
-$0.50 (-0.38%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
19.45B
54 days until earnings call
REGN
Price
$581.06
Change
+$1.45 (+0.25%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
61.43B
62 days until earnings call
Interact to see
Advertisement

BIIB vs REGN

Header iconBIIB vs REGN Comparison
Open Charts BIIB vs REGNBanner chart's image
Biogen
Price$132.15
Change-$0.50 (-0.38%)
Volume$20.76K
Capitalization19.45B
Regeneron Pharmaceuticals
Price$581.06
Change+$1.45 (+0.25%)
Volume$10.34K
Capitalization61.43B
BIIB vs REGN Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB).

Industry description

All of the companies in the innovating biotech group are in the healthcare field, but not all are in the biotech industry. There are biotech firms like Alexion and Regeneron, but there are also drug manufacturers and diagnostic companies in the group. In terms of pharmaceutical manufacturers, you have companies like Amgen and Biogen. On the diagnostics and research side you have Agilent and Thermo Fisher Scientific. Because the group falls under the umbrella of healthcare and because there is diversity among the industries the companies represent, this group is a good representation of major healthcare companies. It should be less vulnerable to economic swings than a number of other groups. The group also has the benefit of being made up of large-cap companies and that also tends to make less volatile.

Market Cap

The average market capitalization across the innovating biotech Theme is 49.16B. The market cap for tickers in the group ranges from 703.55M to 184.93B. TMO holds the highest valuation in this group at 184.93B. The lowest valued company is TBPH at 703.55M.

High and low price notable news

The average weekly price growth across all stocks in the innovating biotech Theme was -2%. For the same Theme, the average monthly price growth was 2%, and the average quarterly price growth was 2%. A experienced the highest price growth at 7%, while QGEN experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the innovating biotech Theme was 22%. For the same stocks of the Theme, the average monthly volume growth was -13% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 100
Price Growth Rating: 52
SMR Rating: 100
Profit Risk Rating: 80
Seasonality Score: -46 (-100 ... +100)

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB).

Market Cap

The average market capitalization across the group is 40.44B. The market cap for tickers in the group ranges from 19.45B to 61.43B. REGN holds the highest valuation in this group at 61.43B. The lowest valued company is BIIB at 19.45B.

High and low price notable news

The average weekly price growth across all stocks in the group was -4%. For the same group, the average monthly price growth was 4%, and the average quarterly price growth was -11%. REGN experienced the highest price growth at -3%, while BIIB experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the group was 2%. For the same stocks of the group, the average monthly volume growth was 7% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 100
Price Growth Rating: 61
SMR Rating: 100
Profit Risk Rating: 100
Seasonality Score: -17 (-100 ... +100)
VS
BIIB vs. REGN commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and REGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (BIIB: $132.65 vs. REGN: $579.61)
Brand notoriety: BIIB and REGN are both notable
BIIB represents the Pharmaceuticals: Major, while REGN is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BIIB: 113% vs. REGN: 67%
Market capitalization -- BIIB: $19.45B vs. REGN: $61.43B
BIIB [@Pharmaceuticals: Major] is valued at $19.45B. REGN’s [@Biotechnology] market capitalization is $61.43B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 4 bullish, 5 bearish.
  • REGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, REGN is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -4.65% price change this week, while REGN (@Biotechnology) price change was -3.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.74%. For the same industry, the average monthly price growth was +15.52%, and the average quarterly price growth was +29.97%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

REGN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (-0.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($61.4B) has a higher market cap than BIIB($19.4B). REGN has higher P/E ratio than BIIB: REGN (14.61) vs BIIB (12.69). BIIB YTD gains are higher at: -13.255 vs. REGN (-18.283). REGN has higher annual earnings (EBITDA): 5.42B vs. BIIB (2.79B). REGN has less debt than BIIB: REGN (2.71B) vs BIIB (6.6B). REGN has higher revenues than BIIB: REGN (14.2B) vs BIIB (10B).
BIIBREGNBIIB / REGN
Capitalization19.4B61.4B32%
EBITDA2.79B5.42B52%
Gain YTD-13.255-18.28373%
P/E Ratio12.6914.6187%
Revenue10B14.2B70%
Total Cash2.76BN/A-
Total Debt6.6B2.71B244%
FUNDAMENTALS RATINGS
BIIB vs REGN: Fundamental Ratings
BIIB
REGN
OUTLOOK RATING
1..100
1669
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5963
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for BIIB (89). This means that REGN’s stock grew significantly faster than BIIB’s over the last 12 months.

REGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that REGN’s stock grew similarly to BIIB’s over the last 12 months.

REGN's SMR Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that REGN’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's Price Growth Rating (59) in the Biotechnology industry is in the same range as REGN (63). This means that BIIB’s stock grew similarly to REGN’s over the last 12 months.

BIIB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as REGN (100). This means that BIIB’s stock grew similarly to REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBREGN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
40%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
47%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 8 days ago
53%
Bullish Trend 9 days ago
61%
Declines
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
45%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FBOT32.010.23
+0.72%
Fidelity Disruptive Automation ETF
SFYX15.900.09
+0.54%
SoFi Next 500 ETF
QDEC30.340.12
+0.40%
FT Vest Nasdaq-100 Buffer ETF – Dec
AQLT26.330.06
+0.22%
iShares MSCI Global Quality Factor ETF
EFAV85.170.02
+0.02%
iShares MSCI EAFE Min Vol Factor ETF

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-2.72%
PFE - BIIB
56%
Loosely correlated
-1.87%
AMGN - BIIB
49%
Loosely correlated
-0.82%
MRK - BIIB
49%
Loosely correlated
-1.02%
NVS - BIIB
46%
Loosely correlated
-0.33%
GSK - BIIB
45%
Loosely correlated
-1.18%
More

REGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ROIV. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-1.25%
ROIV - REGN
41%
Loosely correlated
-0.42%
IDYA - REGN
40%
Loosely correlated
-0.28%
ACLX - REGN
39%
Loosely correlated
+0.50%
IOVA - REGN
38%
Loosely correlated
-7.85%
SMMT - REGN
38%
Loosely correlated
-1.55%
More